28
Participants
Start Date
August 21, 2024
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2029
Linvoseltamab
"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"
RECRUITING
University of Miami, Miami
Regeneron Pharmaceuticals
INDUSTRY
Dickran Kazandjian, MD
OTHER